Big Data in Pharmaceuticals – Thematic Research

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Big Data in Pharma Market Overview

The global data and analytics market in the pharma sector was valued at $1.4 billion in 2020. The healthcare and pharmaceutical industries generate data in abundance from a multitude of sources including physician notes, pathology reports, electronic health records (EHR), patient registries, genomics, clinical trials, social media, wearable devices, and many more. The dataset in question is huge in both size and complexity, rendering traditional data management techniques inefficient for processing.

This big data in pharmaceuticals – thematic research report assesses how big data analytics, combined with other emerging technologies, can be used across the pharma value chain. It provides an overview of the current landscape, including healthcare, technology, regulatory, and macroeconomic trends, as well as key players, while also highlighting opportunities for the use of big data analytics in the future. Moreover, the report provides an analysis of big data-related deals, jobs, and social media activity, highlighting the impact of the COVID-19 pandemic, where relevant.

Big data and analytics market overview for pharma industry

Big data and analytics market overview for pharma industry

For more insights on this report, download a free report sample

What are the key trends that will shape the big data space?

The key trends that will shape the big data space can be divided into four categories: healthcare trends, technology trends, regulatory trends, and macroeconomic trends.

Healthcare trends

The main healthcare trends that will impact the big data space are real-world data, the COVID-19 pandemic, clinical trial design & recruitment, increased use of digital technologies in clinical research, use of AI and big data in drug discovery, drug repurposing, & vaccine development, precision & personalized medicine, industry 4.0, wearables & the collection of health data, and sales & marketing.

Technology trends

Some of the main technology trends that will impact the big data space are cloud computing, 5G, and cybersecurity.

Regulatory trends

The main regulatory trends that will impact the big data space are data privacy & regulatory compliance, cures 2.0, and partnership with regulatory agencies.

Macroeconomic trends

The main macroeconomic trends that will impact the big data space are cost & rising healthcare demand, drug pricing, and the future of work.

What are the different big data value chains in the pharma industry?

The big data value chains in the pharma industry can be divided into three segments: big data generation, big data management, and big data product development.

Big data generation

In healthcare, data is primarily generated by sources such as hospitals, medical groups, and registries. This data is typically generated in the form of EHRs, which include patient health information such as administrative and billing data, demographics, vital signs, and medical history. Internally, the pharma industry can also generate copious amounts of data from clinical trials as well as from operations such as sales and manufacturing.

Big data management

Big data is typically managed in data centers, either in the public cloud, in corporate data centers, or on end devices. Broadly speaking, the objective of big data management is to secure the data (using data governance and security technology), gather insights from the data (using data analysis and business intelligence tools), and manage the data (by applying storage, processing, aggregation, and integration techniques).

Big data product development

Once the data is stored, processed, secured, and analyzed, it can be used within a raft of big data-powered products. By leveraging the wealth of molecular, clinical, and genomic data available, drug R&D can be optimized in the preclinical and clinical stages of development. From a commercial standpoint, data from registries and sales can inform decision-making on marketing and pricing. Finally, pharmaceutical manufacturing can be optimized with big data and IoT technologies including drones, digital twins, smart sensors, etc.

Who are the key public big data vendors in the pharma industry?

The key public big data vendors in the pharma industry are Amazon, International Business Machines, Microsoft, Oracle, and SAP SE.

Who are the key private big data vendors in the pharma industry?

The key private big data vendors in the pharma industry are Antidote Technologies, BenevolentAI, Deep Genomics, Deep Lens, Exscientia, Healx, Insilico Medicine, Lantern Pharma, and Medidata Solutions.

Market report scope

Market size (Year – 2020) $1.4 billion
Forecast period 2021-2025
Key trends Healthcare Trends, Technology Trends, Regulatory Trends, and Macroeconomic Trends
Value chains Big Data Generation, Big Data Management, and Big Data Product Development
Key public big data vendors Amazon, International Business Machines, Microsoft, Oracle, and SAP SE
Key private big data vendors Antidote Technologies, BenevolentAI, Deep Genomics, Deep Lens, Exscientia, Healx, Insilico Medicine, Lantern Pharma, and Medidata Solutions


  • Overview of the current and future use cases of big data analytics in the pharma industry, across the value chain.
  • Insightful review of the healthcare, technology, regulatory, and macroeconomic trends. Each trend is independently researched to provide a qualitative analysis of its implications in the big data space.
  • Reports of the revenue opportunity forecast in the data and analytical markets in the pharma industry from 2020 to 2025, spanning three technology segments and 49 geographical markets.
  • Key players in the big data space, with a focus on technology providers and pharma adopters.
  • Industry analysis of big data in the context of jobs in the pharma industry, use of real-world evidence in post-marketing studies, social media, and several pharma-specific case studies.
  • Deals analysis: outline of key deals within the big data space over the past three years, including mergers and acquisitions, strategic partnerships, and funding.

Reasons to Buy

  • Assess who the leading technology players are in the big data space, as well as leading pharma adopters.
  • See examples of how pharma companies are integrating big data analytics into their value chains.
  • Understand what trends are driving the big data space and challenges that exist for pharma in the space.
  • See how the big data landscape is evolving, with a review of company activity including mergers and acquisitions (M&A), strategic partnerships, and funding deals, as well as job analysis.
  • Assess the impact of COVID-19 on big data analytics.

Dell Technologies
Dassault Systèmes
Eli Lilly
GlaxoSmithKline (GSK)
Hoffmann-La Roche
International Business Machines (IBM)
Insilico Medicine
Johnson & Johnson (J&J)
Sensyne Health

Table of Contents

Executive Summary


Thematic Briefing


Healthcare Trends

Technology Trends

Regulatory Trends

Macroeconomic Trends

Value Chain

Big Data Generation

Big Data Management

Big Data Product Development

Industry Analysis

Market Forecast Size

Survey Data

GlobalData’s Digital Transformation and Emerging Technology in the Healthcare Industry Survey, 2021

GlobalData’s Smart Pharma Survey 2021

Use of Real-World Evidence in Post-Marketing Studies

Analysis of Big Data-Related Jobs in Pharma

Deals Analysis

Mergers and Acquisitions

Strategic Partnerships

Funding Deals

Pharma Case Studies

Sumitomo Dainippon Pharma and Exscientia: Drug Discovery and Development

Syapse’s Learning Health Network and RWE

Unlearn.AI: DiGenesis, Twintelligent RCTs, and Digital Twins

Infor and Bayer: Infor Enterprise Asset Management and Digital Twins

Evidation and Merck: Digital Monitoring with Focus on Alzheimer’s Disease

Social Media Influencers


Leading Big Data Vendors

Specialist Big Data Vendors in Pharma

Leading Big Data Adopters In Pharma



Further Reading

Related Reports


About the Authors

Healthcare Analyst

Managing Analyst

Director of Thematic Analysis

Global Head and EVP of Healthcare Operations and Strategy

| Our Thematic Research Methodology

| About GlobalData

| Contact Us

Frequently asked questions

Big Data in Pharmaceuticals – Thematic Research thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Big Data in Pharmaceuticals – Thematic Research was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Big Data in Pharmaceuticals – Thematic Research in real time.

  • Access a live Big Data in Pharmaceuticals – Thematic Research dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.